Can I read Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma on EtoBox?

Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma by Lorenza Di Guardo; Giovanni Randon; Francesca Corti; Viviana Vallacchi; Alessandra Raimondi; Giovanni Fucà; Marta Bini; Andrea Maurichi; Roberto Patuzzo; Gianfrancesco Gallino; Ilaria Mattavelli; Roberta Ruggeri; Martina Angi; Mara Cossa; Barbara Valeri; Carolina Cimminiello; Mario Santinami; Licia Rivoltini; Filippo Braud; Monica Rodolfo; Michele Del Vecchio is a Medicine article available to read on EtoBox.

What is Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma about?

## Abstract ## Background Outcomes of patients with metastatic melanoma discontinuing BRAF‐targeted therapy for cumulative toxicity after sustained response are unknown. ## Materials and Methods This retrospective case series analysis conducted at a single Cancer Center in Italy included patients with __BRAF__ mutated metastatic melanoma treated with a BRAF inhibitor as a single agent or in combination with a MEK inhibitor between June 1, 2011 and January 1, 2020 and interrupted treatment due to cumulative toxicity after achieving complete response (CR) or long‐lasting partial response (PR; i.e. >12 months). ## Results We included 24 patients with a median treatment duration of 59.4 months (95% confidence interval [CI], 55.4–63.4; range, 12–88). CR and PR were achieved in 71% and 29% of patients, respectively. At a median follow‐up after treatment discontinuation of 37.8 months (95% CI, 33.7–41.9), the 12‐month progression‐free survival after discontinuation (dPFS) rate was 70.8% (95% CI 54.8–91.6) and 24‐month dPFS rate was 58.3% (95% CI, 41.6–81.8). Baseline patient and tumor characteristics as well as treatment duration and best response did not significantly impact on dPFS. Pat

Who reads Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma?

Author

Lorenza Di Guardo; Giovanni Randon; Francesca Corti; Viviana Vallacchi; Alessandra Raimondi; Giovanni Fucà; Marta Bini; Andrea Maurichi; Roberto Patuzzo; Gianfrancesco Gallino; Ilaria Mattavelli; Roberta Ruggeri; Martina Angi; Mara Cossa; Barbara Valeri; Carolina Cimminiello; Mario Santinami; Licia Rivoltini; Filippo Braud; Monica Rodolfo; Michele Del Vecchio

Publisher

Oxford University Press (OUP)

Published

2021

Language

EN

Field

Medicine (Health Sciences)